Legal Opinion
Teva Pharm. United States, Inc. v. Azar
Court of Appeals for the D.C. Circuit
Decided February 26, 2019No. Civil Action No. 18-2394 (RDM)PublishedCited by 4 opinions
1Opinion of the Court
RANDOLPH D. MOSS, United States District Judge
Plaintiff Teva Pharmaceuticals USA, Inc. ("Teva") brings this action to obtain "immediate injunctive and declaratory relief" barring the Food and Drug Administration ("FDA") from "depriving [Teva] of its statutory right to 180 days of marketing exclusivity for its generic version of the brand-name drug Restasis ®." Dkt. 1 at 2 (Compl. ¶ 1). Teva seeks a preliminary injunction. Dkt. 2. The FDA and intervenor defendants-Mylan Pharmaceuticals Inc. ("Mylan"), Deva Holding AS ("Deva"), and Famy Care Private Limited ("Famy Care")-oppose that motion and…
2Cases cited41 opinions
- Ashcroft v. IqbalSupreme Court of the United States · 2009
- Bell Atlantic Corp. v. TwomblySupreme Court of the United States · 2007
- Conley v. GibsonSupreme Court of the United States · 1957
- Lujan v. Defenders of WildlifeSupreme Court of the United States · 1992
- Winter v. Natural Resources Defense Council, Inc.Supreme Court of the United States · 2008
36 more not listed; retrieve them via the Exa API.
3Cited by4 opinions
- Braeburn Inc. v. U.S. Food & Drug Admin.Court of Appeals for the D.C. Circuit · 2019
- Braeburn Inc. v. United States Food and Drug AdministrationDistrict Court, District of Columbia · 2019
- Norwich Pharmaceuticals, Inc. v. BecerraDistrict Court, District of Columbia · 2025
- Norwich Pharmaceuticals, Inc. v. BecerraDistrict Court, District of Columbia · 2023